Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middle-income country settings

Authors: Trishul Siddharthan* MD (1, 2), Matthew R Grigsby* MSPH (1, 2), Dina Goodman MSPH (1, 2), Muhammad Chowdhury MBBS (3), Adolfo Rubinstein MD PhD (4), Vilma Irazola MD (4), Laura Gutierrez MD (4), J Jaime Miranda MD PhD (5, 6), Antonio Bernabe-Ortiz MD MPH (5, 6), Dewan Alam MBBS PhD (7), Bruce Kirenga MBChB (8), Rupert Jones MBBS MD (9), Frederick van Gemert MD (10), Robert A Wise MD (1), William Checkley MD PhD (1, 2).

1. Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, USA.
2. Center for Global Non-Communicable Diseases, School of Medicine, Johns Hopkins University, Baltimore, USA.
3. Centre for Control of Chronic Diseases, icddr,b, Dhaka, Bangladesh.
4. Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
5. CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.
6. Departamento de Medicina, Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru.
7. School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, Ontario, Canada M3J 1P3
8. Makerere Lung Institute, Makerere University, Kampala, Uganda
9. Plymouth University, Plymouth, United Kingdom
10. University of Groningen, University Medical Centre Groningen, Harlingen, Netherlands

Correspondence:
William Checkley, MD, PhD
Division of Pulmonary and Critical Care
School of Medicine
Johns Hopkins University
1830 Monument St, Room 555
Baltimore, MD 21205
E-mail: wcheckl1@jhmi.edu

Word count: 3,499

* Joint first authorship.
ABSTRACT

Rationale: Forty percent of households worldwide burn biomass fuels for energy, which may be most the important contributor to household air pollution.

Objective: Examine the association between household air pollution exposure and COPD outcomes in 13 resource-poor settings.

Methods: We analyzed data from 12,396 adult participants living in 13 resource-poor, population-based settings. Household air pollution exposure was defined as using biomass materials as the primary fuel source in the home. We used multivariable regressions to assess the relationship between household air pollution exposure and COPD outcomes, evaluated for interactions, and conducted sensitivity analyses to test the robustness of our findings.

Results: Average age was 54.9 years (44.2-59.6 years across settings), 48.5% were women (38.3%-54.5%), prevalence of household air pollution exposure was 38% (0.5%-99.6%), and 8.8% (1.7%-15.5%) had COPD. Participants with household air pollution exposure were 41% more likely to have COPD (adjusted OR=1.41, 95% CI 1.18 to 1.68) than those without the exposure, and 13.5% (6.4% to 20.6%) of COPD prevalence may due to household air pollution exposure, compared with 12.4% due to cigarette smoking. The association between household air pollution exposure and COPD was stronger in women (1.70, 1.24 to 2.32) than in men (1.21, 0.92 to 1.58).

Conclusions: Household air pollution exposure was associated with a higher prevalence of COPD, particularly among women, and it is likely the leading population attributable risk factor for COPD in resource-poor settings.

Keywords: COPD; Air Pollution, Indoor/adverse effects; Biomass
INTRODUCTION

Approximately three billion people rely on the burning of solid fuels such as wood, dung, agricultural crop waste, and coal for energy (1), and biomass fuels are the main source of domestic energy for ~40% of households worldwide (2). Households in many low- and middle-income countries (LMICs) often burn biomass inefficiently and with poor ventilation, resulting in exposure to a range of pollutants (3). The resulting household air pollution (HAP) accounts for an estimated 4.3 million premature deaths and 110 million disability-adjusted life years lost each year (4, 5), making it the third leading risk factor for morbidity and mortality globally (6).

Current evidence supports an association between HAP exposure and a range of respiratory diseases including pneumonia, COPD and lung cancer (7-10). COPD, in particular, is a salient consequence of HAP exposure since it poses a considerable socioeconomic burden and disproportionally affects impoverished populations in LMICs (11). Previous studies have demonstrated that the relationship between HAP exposure and respiratory health outcomes is strongest among women and children who have the most intense exposure (12). Two recent population-based studies in Latin America found that women with HAP exposure were more likely to have COPD than those who did not have the exposure (13, 14).

Few population-based studies have evaluated the attributable risk for COPD due to HAP exposure. Here we describe the relationship between HAP exposure and COPD in 13 LMIC settings. These settings represent a diversity of geographies, ethnicities, variations in altitude, and degrees of urbanization in resource-poor settings of Latin America, Sub-Saharan Africa and Southeast Asia.
METHODS

Study setting

We pooled data from five population-based studies spanning six countries and 13 settings in Latin America, Sub-Saharan Africa and Southeast Asia. Included studies were sponsored by United States National Institutes of Health/National Heart, Lung, and Blood Institute and United Health Chronic Disease Initiative (http://www.nhlbi.nih.gov/about/org/globalhealth/centers), the Fogarty International Center of the United States National Institutes of Health, and the FRESH AIR Study Group. To be eligible, studies had to contribute data with the following specifications: 1) adults aged ≥ 18 years, 2) site located in a World Bank defined LMIC participating within the above described networks, 3) conducted a population-based study, 4) performed post-bronchodilator spirometry in those with obstruction, and willing to share data for pooled analysis. Specifically, data were compiled from the Pulmonary Risk in South America (PRISA) study, conducted by the Institute for Clinical Effectiveness and Health Policy (IECS) in two sites in Argentina (Marcos Paz and Bariloche), one in Chile (Temuco), and one in Uruguay (Canelones), the CRONICAS Cohort Study in Peru, conducted by the CRONICAS Centre of Excellence for Chronic Diseases at Universidad Peruana Cayetano Heredia and Johns Hopkins University, and a longitudinal study in Bangladesh, conducted by the Centre for Control of Chronic Diseases at the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Lung Function Study in Nakaseke and Uganda (LiNK) and the FRESH AIR Uganda, conducted by the Makerere Lung Institute. Both PRISA and CRONICAS studies are prospective longitudinal studies with multiple years of follow up that started in 2010 (15, 16). icddr,b conducted a longitudinal study from 2011 to 2012 (17). The Lung Function Study in Nakaseke and Uganda (LiNK) is an ongoing longitudinal study with baseline data collected in 2015. FRESH AIR Uganda is a cross-sectional study conducted in 2012 in rural Masindi (18).
Study Design

PRISA and CRONICAS used age- and sex-stratified random sampling whereas the Bangladesh study used simple random sampling of available census data at each site. LiNK used a sampling technique outlined by the WHO, while FRESH AIR used a multi-level sampling approach (16, 17, 19-24). We limited our analysis to participants aged 35-95 years to match reference equation upper age limits (25). All studies obtained informed consent from local and international ethics boards, and all investigators required confidentiality training for field workers. Details can be found elsewhere (16, 17, 19-21).

Spirometry

All sites followed joint ATS/ERS recommendations when performing and grading spirometry. PRISA, CRONICAS, LiNK, and Bangladesh used similar spirometry devices (ndd, Zurich, Switzerland), while FRESH AIR used Pneumotrac spirometers (16, 17, 20, 21). Pre- and post-bronchodilator forced expiratory volumes (FEVs) were measured for all individuals in PRISA and CRONICAS, whereas other studies only took post-bronchodilator measurements on those who screened positive for obstruction on pre-bronchodilator spirometry (FEV₁/FVC ≤ 0.7 in FRESH AIR and the Bangladesh studies, and FEV₁/FVC ≤ lower limit of normal in LiNK).
Definitions

We defined COPD as having a post-bronchodilator FEV$_1$/FVC Z-score $\leq -1.64$ SDs of the Global Lung Function Initiative (GLI2012) mixed ethnic reference population (26). COPD severity was categorized according to the GOLD strategy (25, 27). Pack-years of smoking was defined as the number of packs smoked per day multiplied by the number of years smoking. Participants were considered to have symptomatic COPD if they had wheeze, cough, or phlegm currently or in the last 12 months. We defined restrictive spirometric pattern as a pre-bronchodilator FVC Z-score $< -1.64$ and no spirometric evidence of COPD (28); daily smoking as having $\geq 1$ cigarette/day; and, HAP exposure if biomass was the primary source of fuel in the home. We defined lung function reversibility as the difference between post- and pre-bronchodilator FEVs was $>200$ mL and/or the percent increase was $>12\%$.

Biostatistical analysis

Our primary analytical plan was to characterize the association between HAP exposure and COPD. We conducted secondary analyses to assess the association between HAP exposure and other COPD outcomes, namely severity and the presence of concomitant respiratory symptoms, and pre-bronchodilator FEVs; and, between HAP exposure and restrictive spirometric pattern.

For our primary analysis, we used multivariable alternating logistic regressions (ALR) to model the association between HAP exposure and COPD, adjusted for age, sex, daily cigarette smoking, body mass index, post-treatment pulmonary tuberculosis and secondary education (i.e., confounders). ALR is a variant of generalized estimating equations where the association between pairs of participants for a particular site is modeled with log odds ratios instead of correlations (29). In sensitivity analyses, we used the Mantel-Haenszel method to estimate unadjusted odds ratios weighted by site, and multivariable random effects logistic regression to
determine if our findings were robust to the approach chosen to model heterogeneity across settings (Online Supplement) (30, 31). We also examined for effect modification by sex, age (≥55 or <55 years), self-reported daily cigarette smoking, and having secondary education. We used adjusted odds ratio estimates to calculate the population attributable fraction of COPD due to HAP exposure using Levin’s formula, i.e., \( PAR = \frac{p \times (OR-1)}{1+p \times (OR-1)} \) (32).

For secondary analyses, we used multivariable random effects ordinal logistic regressions to examine the association between HAP exposure and COPD severity (none, mild, moderate or severe/very severe COPD) or symptomatic COPD (none, asymptomatic COPD and symptomatic COPD) adjusted for confounders (vide supra). To graphically assess for proportionality of odds, we compared the ORs and corresponding 95% CIs obtained for each variable from a logistic regression model evaluated at each of the threshold points for the above ordinal scales (See Online Supplement). We used ALR to examine the association between HAP exposure and either having restrictive spirometric pattern or reversibility adjusted for confounders. We used multivariable linear mixed-effects models with a random intercept by site to study the association between HAP exposure and pre-bronchodilator FEVs accounting for an interaction with age and adjusted for confounders (30, 33, 34).

In sensitivity analyses, we used the GLI2012 Caucasian reference values to determine if our estimates were consistent regardless of the reference chosen; used pack-years smoked instead of daily smoking to rule out residual confounding by not adjusting for frequency of smoking exposure; conducted leave-one-site-out and ten-fold cross validation analyses to determine if one site or subset of data heavily influenced exposure-outcome relationships, respectively; limited analyses to sites with a prevalence of HAP exposure <95% and >5%, or with at least 5 participants in each category of the contingency table between HAP exposure and COPD to
determine if these sites heavily influenced exposure-outcome relationships (Online Supplement).

Analyses were performed in R using the lme4, gmodels, ggplot2, alr, doParallel and ordinal packages (35, 36).
RESULTS

Population Characteristics
The 13 sites contributed data on 13,023 participants but 12,396 met eligibility criteria and had complete data for analysis (Figure 1). Fifty-eight percent of the study sample lived in Latin America, 28% in Southeast Asia, and 14% in Sub-Saharan Africa. Average age among participants in the study sample was 54.9 years (range of means across settings 44.2-59.6 years; p<0.001 for differences between sites), 48.5% were women (range of proportions across settings 38.3%-54.5%; p<0.001) and the overall prevalence of HAP exposure was 38% (0.5%-99.6%; p<0.001). There were no differences in COPD prevalence (8.9% vs. 8.8%; p=0.97) between excluded and included participants; however, those who were excluded had a higher prevalence of HAP exposure (92% vs 38%; p<0.001), were younger (46.0 years vs. 54.9 years; p<0.001), and were more likely to be women (54.9% vs. 48.5%; p=0.002). Self-reported biomass use ranged from 0.5% in Marcos Paz, Argentina to 99.6% in Nakaseke, Uganda. Daily cigarette smoking ranged from 0.2% in rural Puno, Peru to 36.2% in Masindi, Uganda. All sites were located in resource-poor settings in LMICs with a variety of kitchen layouts (Figure 2).

Epidemiology of COPD
The overall prevalence of COPD was 8.8% with a range of 1.7% in Kampala, Uganda to 15.5% in Masindi, Uganda. Men had a higher prevalence of COPD than women (10.3% vs. 7.2%; p<0.001), however, there was significant heterogeneity in the prevalence of COPD by sex across sites (Figure 3). Among those with COPD, 394 (36.1%) were mild, 524 (48.0%) were moderate, and 173 (15.9%) were severe/very severe; however, there was also substantial heterogeneity in severity profiles across settings (Figure 3). For example, the prevalence of severe COPD ranged from 0% in both rural and urban Puno, Peru to 26.5% in Dhaka, Bangladesh. Men also had a higher prevalence of moderate (53.4% vs. 39.8%; p <0.001) or severe/very severe COPD (19.3% vs. 10.6%; p<0.001) than women. In site-weighted analyses,
daily cigarette smokers were more likely to have COPD than participants who did not smoke daily (Mantel-Haenszel OR=2.55; 95% CI 2.17 to 3.00). When stratified by sex, both men (Mantel-Haenszel OR[OR_{MH}]=2.30, 1.89 to 2.80) and women (OR_{MH}=1.83, 1.35 to 2.48) who were daily smokers were more likely to have COPD than those who were not smokers.

**HAP exposure and COPD outcomes**

Participants with HAP exposure had a higher prevalence of COPD than those without the exposure (10.8% vs. 7.6%; \(p<0.001\)). In site-weighted analyses, participants with HAP exposure were more likely to have COPD than those without the exposure (OR_{MH}=1.68, 95% 1.29 to 2.19). In multivariable-adjusted analysis accounting for clustering by site, participants with HAP exposure were more likely (adjusted OR=1.41, 95% CI 1.18 to 1.68) to have COPD than those without the exposure (Figure 4). Participants with HAP exposure also had a greater odds of having more severe disease (adjusted OR=1.51, 95% CI 1.16 to 1.96) or having symptoms (adjusted OR=1.50, 95% CI 1.15 to 1.97).

We plotted interaction effects between HAP exposure and potential effect modifiers on the odds of having COPD (Figure 4), and found that the association between HAP exposure and COPD was stronger in women (adjusted OR=1.70, 95% CI 1.24 to 2.32) than in men (1.21, 0.92 to 1.58). We also found that HAP exposure was associated with a higher odds of having COPD among participants aged ≥55 years (1.43, 1.09 to 1.87) and a marginally higher odds of having COPD for those aged <55 years (1.32, 0.97 to 1.78). While the prevalence of COPD between participants with HAP exposure was higher at any age when compared to those without the exposure, the difference by HAP exposure status was greater at older ages (Figure 5).

We estimated that 13.5% (95% CI 6.4% to 20.6%) of the COPD prevalence in our study sample was due to HAP exposure, in contrast to 12.4% due to daily cigarette smoking, 9.4% due to
lower education and 6.6% due to post-treatment pulmonary tuberculosis. When stratified by sex, the PAF was higher in women (21.0%, 95% CI 8.4% to 33.5%) than in men (7.3%, -3.1% to 18.0%). When stratified by region, the PAF was highest in Sub-Saharan Africa (28.2%, 14.6% to 39.6%), followed by Southeast Asia (17.8%, 8.7% to 26.6%) and Latin America (6.4%; 2.9% to 10.3%).

In sensitivity analyses, we found that using a Caucasian reference for FEVs did not affect the direction or magnitude of reported exposure-outcome associations. Similarly, analyses using pack-years smoked instead of daily smoking showed almost identical results (Online Supplement). Both leave-one-site-out and ten-fold cross-validation analyses revealed that no single site or small groups of participants appeared to have heavily influenced the association between HAP exposure and COPD. Moreover, the association between HAP exposure and COPD was consistent in magnitude and direction when we limited our data to sites with <95% and >5% prevalence of HAP exposure, or sites with at least 5 participants in each category of the contingency table between HAP exposure and COPD (Online Supplement).

**HAP exposure and lung function**

We plotted Z-scores of pre-bronchodilator FEV₁ by deciles of age and stratified by HAP exposure (Figure 6). On average, participants with HAP exposure had lower pre-bronchodilator FEV₁, FVC and FEV₁/FVC Z-scores at any age when compared to those without the exposure. There were notable differences in the trends with age, however. Specifically, across all age deciles, participants with HAP exposure had a consistently lower pre-bronchodilator FEV₁ Z-score when compared to participants who did not have the exposure. In contrast, differences in FVC Z-scores between participants with and without HAP exposure were greater in younger ages whereas differences in FEV₁/FVC Z-scores were greater at older ages. These trends remained consistent in multivariable regression analyses that accounted for heterogeneity
across sites. Specifically, participants with HAP exposure had: a marginally lower adjusted pre-bronchodilator FEV₁ Z-score (-0.11 SD, 95% CI -0.24 to 0.03 SD) than those who did not have the exposure across all ages, with no interaction effect between HAP exposure and age (p=0.07); a lower pre-bronchodilator FVC Z-score at age 35 years (-0.14 SD, -0.28 to -0.004 SD) but not at age 60 years (-0.02 SD, -0.13 to 0.10 SD); and, no difference in pre-bronchodilator FEV₁/FVC Z-score at age 35 years (0.02 SD, -0.09 to 0.14 SD) but a lower pre-bronchodilator FEV₁/FVC Z-score at 60 years (-0.25 SD, -0.34 to -0.15 SD). In subset analysis of studies with both pre- and post-bronchodilator spirometry, we found that participants with HAP exposure were more likely to have lung function reversibility than those without the exposure at younger ages (adjusted OR at 35 years=1.62, 95% CI 1.18 to 2.24) but not at older ages (adjusted OR at 60 years=1.27, 0.93 to 1.74). Sensitivity analyses showed comparable results when using Caucasian reference values (Online Supplement).

**HAP exposure and restrictive spirometric patterns**

Participants with HAP exposure had a lower prevalence of restrictive spirometric patterns than those who did not have the exposure (11.4% vs. 14.8%; p<0.001) and this difference was consistent across all ages (Figure 4). In site-weighted analysis, participants with HAP exposure had similar odds of having restrictive spirometric pattern (OR₉₅=0.83, 95% CI 0.64 to 1.06) when compared to those without the exposure. There was a similar effect of HAP exposure when using multivariable analyses accounting for clustering by site (adjusted OR=0.86, 95% 0.72 to 1.04). Site-specific analysis showed a wide range of adjusted odds ratios, ranging from 0.46 in Nakaseke, Uruguay to 3.92 in Masindi, Uganda (Online Supplement).
DISCUSSION
We used data from pooled population-based cohorts to examine the association between HAP exposures and COPD outcomes across 13 diverse LMICs. We found a positive association between HAP exposure and COPD outcomes in 12,396 participants, namely a higher overall prevalence and worse disease severity both in terms of symptoms and lung function. This was especially true among women and in participants from Sub-Saharan Africa, for whom 21% and 28% of COPD prevalence was attributed to HAP exposure, respectively. Our data suggests that HAP exposure is likely the leading population attributable risk factor for COPD in our resource-poor settings, even above that of cigarette smoking.

The association between HAP exposure and COPD outcomes have been well studied but with variable results. A meta-analysis of 11 studies found that women and men over age 30 years with HAP exposure had 3.2 and 1.8 times the risk of having COPD than those without the exposure, respectively (12). A more recent meta-analysis of 25 studies found that women with HAP exposure had 2.4 times the odds of having COPD when compared to those without the exposure (10). The reported relationships between HAP exposure and COPD in our pooled analyses for resource-poor settings in LMICs were positive but were more modest in magnitude when compared to the findings of previous two meta-analyses. There are several potential reasons for these different results. First, the above meta-analyses included case-control studies or convenience samples whereas our studies were all population-based. Second, these meta-analyses only included participants who lived in households with high particulate matter concentrations. Third, previous studies used fixed cutoffs to identify COPD, which may underestimate its prevalence in younger individuals and over-estimate it in older individuals (13, 37, 38). In our analysis, we used the lower fifth percentile of post-bronchodilator FEV₁/FVC to identify COPD, which may capture a more accurate prevalence in the general population.
In a recent analysis, BOLD investigators did not find an association between biomass fuel smoke exposure and COPD among non-smokers using data from 12 countries when evaluated for the overall study population or when stratified into high-income countries (HICs) and LMICs (39). In contrast, our study sample is limited to resource-poor settings in LMICs only and did not include studies conducted in HICs. Specifically, HAP exposure in HICs traditionally do not result in same levels of smoke exposure as that observed in LMICs (40). This may be because homes in HICs use biomass fuels mostly for heating with well-ventilated chimneys or stoves in contrast to poorly ventilated open-fire stoves used in LMICs. This may result in important misclassification of exposure, which could be non-differential in nature. For example, the analysis of BOLD data revealed that 71% of households in Lexington, Kentucky (USA) used biomass fuels when compared to only 46% of households in Ile-Ife (Nigeria). There are other similar examples of a disconnect between HAP exposure in HIC and LMICs.

Pollutants caused by incomplete burning of biomass fuel have been linked to abnormal inflammatory response of the lungs and, thus, COPD (41). HAP exposure triggers a lung-specific and systemic inflammatory state that heightens mechanisms of cell damage, such as oxidative stress (42). Particulate matter, for instance, has been thought to stimulate an inflammatory response in airway macrophages and respiratory epithelial (1). Beyond the direct effect of toxic pollutants on the lungs, HAP exposure affects lung function across the lifespan of an individual. Proposed mechanisms during intrauterine development include deposition of particulate matter in maternal lung tissue resulting in impaired fetal growth, and carbon monoxide exposure may result in reduced oxygen delivery to the fetal placenta (12). HAP exposure may also be associated with a higher prevalence of childhood pneumonia (12). These early life events result in lower baseline lung function in early adulthood and accelerated lung function decline which predisposes individuals to COPD (43, 44).
We found that participants with HAP exposure had a lower pre-bronchodilator FEV\(_1\) at all ages, a lower pre-bronchodilator FEV\(_1\)/FVC that became more pronounced at older ages, and a higher odds of having lung function reversibility at younger ages but not at older ages when compared to those without the exposure. These findings support the notion that HAP exposure has deleterious effects on lung function and worsen airflow obstruction that may become non-reversible with older age. The effect of HAP exposure on FVC was not as pronounced, explaining the overall decrease in pre-bronchodilator FEV\(_1\)/FVC among those exposed to biomass over time. A number of cross-sectional studies have found exposure-response relationships between HAP and lung function (45, 46). Longitudinal studies, however, have not demonstrated improved FEV\(_1\) with reduction in HAP exposure, although analysis of lung function has so far been limited due to the short follow-up periods (47). Individuals exposed to biomass fuel smoke had higher chances of airway reversibility at younger ages but not at older ages, suggesting that chronic inflammation from HAP exposure is associated with the development of chronic airway disease.

Our analysis has some important strengths. First, we used large and diverse population-based sample with harmonized variables, allowing for the adjustment of \textit{a priori} known risk factors for COPD. Second, we only included studies conducted in LMICs where biomass are commonly burned in poorly ventilated areas (40). Third, we used the lower limit of normal to diagnose COPD instead of a fixed cutoff which could lead to over-diagnosis especially in older participants (48). Fourth, our sensitivity analyses did not identify a single site or subgroup of participants that heavily influenced exposure-outcome relationships. Fifth, the prevalence of HAP exposure in our study sample is consistent with previously published reports of worldwide prevalence (2).
Our analysis also has some potential shortcomings. Our inferences are based on observational data that may be affected by unmeasured confounding. Longitudinal studies with repeated assessments of lung function and exposure to HAP or randomized control trials including experimental elimination of HAP are needed to establish temporal relationships and ultimately causality. As with previous studies, we were unable to quantify direct exposure to biomass beyond self-reported questionnaires. Some of the included study sites, however, have previously published HAP concentrations among those with and without HAP exposure (49).

Second, the GLI2012 mixed ethnic reference population may not accurately represent all individuals in our study, which may help explain inconsistent findings. To mitigate this concern, we conducted sensitivity analyses with other reference populations. Third, we were unable to ascertain subject-specific time period of biomass fuel smoke exposure using the available pooled data. However, previous studies in LMICs have reported that number of years of biomass exposure are closely linked to age, particularly among women who use biomass fuels daily for cooking (13). Time or dose-dependent relationships may be reflected in the higher odds of having COPD among women vs. than of men with HAP exposure when compared to those without the exposure. Fourth, we did not have data on occupational exposure history or pack-years of tobacco smoking, which may result in residual confounding. Fifth, HAP exposure is closely linked to a lower socioeconomic status (SES), which is also a known risk factor for COPD (19). For this analysis, we used secondary education which is a proxy for SES but could not harmonize across other factors, which again may result in residual confounding.

In this analysis we also calculated the population attributable fractions, i.e., the proportional reduction in disease if exposure to a risk factor were mitigated. Accordingly, we estimated that there would be a 13.5% reduction in COPD prevalence if HAP exposure were eliminated compared to 12.4% if cigarette smoking were eliminated. This finding emphasizes the importance of HAP reduction strategies as public health intervention to reduce the burden of
COPD among LMICs. However, to date, a number of trials using cleaner biomass-burning cookstoves aimed at reducing HAP exposure have failed to produce meaningful reductions in HAP exposure. Future intervention trials with clean fuels will ultimately be needed to determine the effect of HAP exposure on multiple health outcomes, including those on lung function and COPD.

Conclusions
We found that HAP exposure was associated with COPD in resource-poor settings of LMICs, and it was associated with both severity of disease and overall lung function. Women were the most affected, and regions like Sub-Saharan Africa may share a disproportionate share of the global burden from this risk factor.
Acknowledgments

We are grateful to the following individuals for providing useful and insightful comments to this manuscript: Shyfuddin Ahmed (icddrb, Dhaka, Bangladesh), Sonia Pervin (icddrb, Dhaka, Bangladesh), Khaled Hasan (icddrb, Dhaka, Bangladesh), and Vilma Irazola (Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina). We gratefully acknowledge the study participants and the commitment of donors who support CRONICAS, PRISA, ACCESS and icddr,b. We are grateful to Brooks Morgan, Sonnet Gaertner, and Reuben Mathew for providing photographs of the sites. This study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institute of Health in the United States, under contract no HHSN268200900033C and HHSN26820900032C. WC was additionally supported by a Pathway to Independence Award (R00HL096955). TS was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the National Institutes of Health (1F32ES028577). AR was supported by the National Institutes of Health Office of the Director, Fogarty International Centre and National Heart, Blood, and Lung Institute through the International Clinical Research Fellows Program at Vanderbilt University (R24 TW007988) and the American Relief and Recovery Act.
References


Table 1: Sociodemographic characteristics stratified by site. Mean and SD pack-years smoked was calculated among individuals who smoked.

<table>
<thead>
<tr>
<th></th>
<th>Bariloche</th>
<th>Canelones</th>
<th>Dhaka</th>
<th>Kampala</th>
<th>Lima</th>
<th>Marcos Paz</th>
<th>Masindi</th>
<th>Matlab</th>
<th>Nakaseke</th>
<th>Rural Puno</th>
<th>Temuco</th>
<th>Tumbes</th>
<th>Urban Puno</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of people</td>
<td>1099</td>
<td>851</td>
<td>1672</td>
<td>596</td>
<td>997</td>
<td>1236</td>
<td>414</td>
<td>1824</td>
<td>721</td>
<td>500</td>
<td>1038</td>
<td>945</td>
<td>503</td>
</tr>
<tr>
<td>COPD positive, %</td>
<td>7.1 (78)</td>
<td>9.3 (79)</td>
<td>9.7 (162)</td>
<td>1.7 (10)</td>
<td>5.6 (56)</td>
<td>13.8 (171)</td>
<td>15.5 (64)</td>
<td>15.3 (279)</td>
<td>7.4 (53)</td>
<td>8.8 (44)</td>
<td>5.2 (54)</td>
<td>1.7 (16)</td>
<td>5.0 (25)</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>57.6 (7.8)</td>
<td>59.6 (8.5)</td>
<td>51.8 (9.3)</td>
<td>44.2 (8.9)</td>
<td>54.9 (11.8)</td>
<td>58.8 (8.2)</td>
<td>49.7 (12.5)</td>
<td>55.1 (10.6)</td>
<td>49.1 (11.2)</td>
<td>55.5 (12.5)</td>
<td>59.2 (8.5)</td>
<td>55.5 (13.1)</td>
<td>55.2 (12.1)</td>
</tr>
<tr>
<td>Height in centimeters, mean (SD)</td>
<td>161.2 (9.8)</td>
<td>162.2 (9.3)</td>
<td>155.5 (9.0)</td>
<td>162.1 (8.7)</td>
<td>154.8 (8.5)</td>
<td>161.7 (9.4)</td>
<td>161.3 (9.3)</td>
<td>153.9 (8.3)</td>
<td>159.9 (8.0)</td>
<td>155.4 (8.0)</td>
<td>160.3 (9.1)</td>
<td>158.4 (8.7)</td>
<td>156.9 (9.0)</td>
</tr>
<tr>
<td>Number of males, % (n)</td>
<td>61.2 (673)</td>
<td>61.7 (525)</td>
<td>45.5 (761)</td>
<td>48.7 (290)</td>
<td>49.2 (491)</td>
<td>59.9 (740)</td>
<td>50.0 (207)</td>
<td>46.0 (839)</td>
<td>45.9 (331)</td>
<td>47.0 (235)</td>
<td>54.7 (568)</td>
<td>50.2 (474)</td>
<td>49.5 (249)</td>
</tr>
<tr>
<td>Education ≥ secondary, % (n)</td>
<td>49.9 (548)</td>
<td>49.8 (424)</td>
<td>44.1 (738)</td>
<td>20.8 (124)</td>
<td>45.7 (456)</td>
<td>34.3 (424)</td>
<td>16.9 (70)</td>
<td>18.8 (342)</td>
<td>7.1 (51)</td>
<td>33.4 (167)</td>
<td>70.7 (734)</td>
<td>36.0 (340)</td>
<td>65.2 (328)</td>
</tr>
<tr>
<td>Biomass as primary source of fuel, % (n)</td>
<td>23.1 (254)</td>
<td>5.1 (43)</td>
<td>3.6 (61)</td>
<td>93.5 (557)</td>
<td>2.4 (24)</td>
<td>0.5 (6)</td>
<td>92.8 (384)</td>
<td>98.1 (1789)</td>
<td>99.6 (718)</td>
<td>95.4 (477)</td>
<td>22.4 (233)</td>
<td>16.7 (158)</td>
<td>2.0 (10)</td>
</tr>
<tr>
<td>Daily smokers, % (n)</td>
<td>23.9 (263)</td>
<td>21.7 (185)</td>
<td>6.5 (108)</td>
<td>8.7 (52)</td>
<td>3.2 (32)</td>
<td>22.7 (281)</td>
<td>36.2 (150)</td>
<td>9.0 (164)</td>
<td>6.9 (50)</td>
<td>0.2 (1)</td>
<td>14.9 (155)</td>
<td>5.6 (53)</td>
<td>2.2 (11)</td>
</tr>
<tr>
<td>Pack-years smoked, mean (SD)</td>
<td>23.0 (18.3)</td>
<td>35.2 (30.0)</td>
<td>20.6 (18.0)</td>
<td>8.7 (9.4)</td>
<td>2.7 (9.0)</td>
<td>31.4 (22.1)</td>
<td>6.7 (13.1)</td>
<td>19.8 (15.9)</td>
<td>6.5 (7.7)</td>
<td>1.3 (4.3)</td>
<td>13.0 (14.2)</td>
<td>5.3 (12.9)</td>
<td>2.7 (7.2)</td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>29.0 (5.8)</td>
<td>29.6 (6.2)</td>
<td>24.6 (4.9)</td>
<td>26.0 (5.3)</td>
<td>28.4 (4.4)</td>
<td>30.1 (5.8)</td>
<td>22.9 (4.3)</td>
<td>20.6 (3.6)</td>
<td>23.8 (4.5)</td>
<td>25.2 (3.7)</td>
<td>29.1 (4.9)</td>
<td>28.3 (4.7)</td>
<td>27.9 (4.4)</td>
</tr>
<tr>
<td>BMI (kg/m²), % (n)</td>
<td>0-18.5</td>
<td>0.9 (10)</td>
<td>1.1 (9)</td>
<td>10.3 (173)</td>
<td>3.4 (20)</td>
<td>0.1 (1)</td>
<td>0.5 (6)</td>
<td>9.4 (39)</td>
<td>30.5 (556)</td>
<td>8.2 (59)</td>
<td>1.6 (8)</td>
<td>0.5 (5)</td>
<td>0.4 (4)</td>
</tr>
<tr>
<td></td>
<td>18.5-25</td>
<td>25.0 (275)</td>
<td>20.0 (170)</td>
<td>44.7 (748)</td>
<td>46.5 (277)</td>
<td>22.0 (219)</td>
<td>17.9 (221)</td>
<td>67.1 (278)</td>
<td>58.3 (1063)</td>
<td>61.0 (440)</td>
<td>50.4 (252)</td>
<td>16.7 (173)</td>
<td>23.7 (224)</td>
</tr>
<tr>
<td></td>
<td>25-30</td>
<td>36.2 (398)</td>
<td>36.0 (306)</td>
<td>32.7 (546)</td>
<td>28.9 (172)</td>
<td>45.4 (453)</td>
<td>35.1 (434)</td>
<td>17.4 (72)</td>
<td>9.6 (176)</td>
<td>21.1 (152)</td>
<td>37.2 (186)</td>
<td>46.2 (480)</td>
<td>44.3 (419)</td>
</tr>
<tr>
<td></td>
<td>30+</td>
<td>37.9 (416)</td>
<td>43.0 (366)</td>
<td>12.3 (205)</td>
<td>21.3 (127)</td>
<td>32.5 (324)</td>
<td>46.5 (575)</td>
<td>6.0 (25)</td>
<td>1.6 (29)</td>
<td>9.7 (70)</td>
<td>10.8 (54)</td>
<td>36.6 (380)</td>
<td>31.5 (298)</td>
</tr>
</tbody>
</table>
Figure 1. Flow chart of study participants included in pooled analysis. A total of 13,023 participants were enrolled at 13 sites. 878 were excluded due to having an age < 35 or > 95 years, missing lung function or missing information on self-reported biomass fuel use. A total of 12,396 were included in final analysis. An additional 251 individuals had missing information on age, sex, site, BMI, secondary education, daily cigarette use or history of post-treatment tuberculosis (n.b., some individuals were missing more than one variable).
Figure 2. Typical kitchen and stoves in selected sites. Top row, from left to right: Puno Peru; Lima, Peru; Tumbes, Peru; and Nakaseke, Uganda. Bottom row, from left to right: Kampala, Uganda; Dhaka, Bangladesh; Matlab, Bangladesh; and Temuco, Chile.
**Figure 3. Sex-, site and severity-stratified prevalences of COPD.** The prevalence of COPD was stratified by sex (women on the left, men on the right) and severity as defined by lung function (in shades of grey) across the 13 LMICs sites. Sites were ordered according to the overall prevalence of COPD from lower (top) to higher (bottom). Overall COPD was more prevalent among men, though in rural settings the prevalence was higher among women. COPD was more severe (lower FEV₁) in the urban settings and among men.
Figure 4. Interaction effects between HAP exposure and interactions with sex, daily smoking, age, education on COPD outcomes, and association between HAP exposure and ordinal outcomes of disease severity by lung function and symptoms. Effect modification by site between HAP exposure and potential effect modifiers on the odds of having COPD was calculated. HAP exposure was associated with a higher odds of having COPD in women, among those who completed secondary education and among participants aged ≥55 years and a marginally higher odds of having COPD for those aged <55 years.
Figure 5. Prevalence of COPD and restricted respiratory patterns by deciles of age stratified by household air pollution exposure. We calculated point prevalences of COPD at each age decile and by household air pollution exposure status. Values on the x-axis represent the starting age for each decile. HAP exposure status was stratified according to participants who reported using biomass as the predominant fuels (B) and those who did not use biomass as the predominant fuel (C). We used smoothing splines to describe the relationship between HAP exposure status and COPD or RSP prevalence across age deciles. The broken liens summarize trends for participants with HAP exposure and continuous lines summarize trends for those without the exposure.
Figure 6. Mean pre-bronchodilator FEV$_1$, FVC and FEV$_1$/FVC Z-scores by deciles of age stratified by HAP exposure. We calculated average Z-scores for FEVs at each age decile and by household air pollution exposure status. Values on the x-axis represent the starting age for each decile. HAP exposure status was stratified according to participants who reported using biomass as the predominant fuels (B) and those who did not use biomass as the predominant fuel (C). The broken lines summarize trends for participants with HAP exposure and continuous lines summarize trends for those without the exposure.